Dr. Kathryn (Kate) Monroe, PhD

Director and Principal Scientist at Denali Therapeutics

Speaker

I conducted my graduate training in the lab of Dr. Russell Vance at University of California, Berkeley. In the Vance lab, I examined mechanisms by which the innate immune system senses and distinguishes between pathogenic and non-pathogenic bacteria. My postdoctoral training was in Dr. Warner Greene's lab at the Gladstone Institute of Virology and Immunology. My career in biotech began at Alector and has continued for the past 8+ years at Denali Therapeutics. In the Discovery Biology group, my team pursues novel drug discovery for Alzheimer’s Disease (AD) and other CNS diseases by carrying out target discovery, biological validation, and identification of transport vehicle enabled large molecule drug candidates.